Sorcero, the AI-powered intelligence platform for life sciences, today announced $42.5 million in Series B financing led by NewSpring Growth, NewSpring Capital’s dedicated growth equity strategy that invests in fast-growing, industry-transforming technology companies. They are joined by Leawood Venture Capital and Blu Ventures, bringing the company’s total capital raised to $59 million. The latest funding allows Sorcero to accelerate expansion across medical affairs, safety, scientific communications, and medical device segments globally, continue scaling its platform for a medical-insights driven engagement model, and meet life sciences’ critical need to drive adoption of breakthrough therapies.
One-third of the top 30 global pharma companies use Sorcero to discover actionable insights from their medical data and drive effective evidence-based, personalized engagement with healthcare professionals (HCPs). Using Sorcero, companies are improving productivity in generating scientific evidence by up to 92%, accelerating insight generation by up to 72%, and delivering published evidence, manuscripts, and value dossiers two to five months faster than manual efforts.
Read More – Tailor Closes Series A Funding; Brings Total to $37M
The Sorcero Intelligence Platform includes Sorcero Medical™, Sorcero SciComms™, Sorcero Safety™, Sorcero Medtech™, transforming how therapies get to market, accelerating content production, and improving patient outcomes. Sorcero uniquely combines Agentic AI specifically trained for life sciences, the industry’s largest medically-enriched data pool, and a platform architecture designed for regulatory and privacy needs of life sciences.
“Our vision is to create a unified intelligence platform for the precision medicine era,” said Dipanwita Das, CEO and co-founder at Sorcero. “We’re pioneering a new evidence-based medical affairs model where science, personalized for physicians, drives engagement and product adoption. This puts doctors’ evidence needs at the center and helps life sciences generate real-world insights radically faster, identify patients in need of specific treatments, and continually improve patient outcomes to drive healthcare provider adoption.”
Optimizing life sciences for a disruptive era
Precision medicine and specialty drugs now represent over 80% of new approved products. Companies spend billions on research and development, but new complex medicines take years to secure broad adoption and coverage, with effective therapies often failing to reach eligible patients. With over 1,300 drugs in Phase III development and with 76% of new products securing less than 50% payor coverage in six months, quality and speed-to-market of scientific publishing and evidence are critical and medical affairs teams require new approaches to deliver the precision targeting and evidence today’s therapies require.
An estimated 70% of healthcare professionals (HCP) believe that pharma representatives don’t understand their needs and 62% are overwhelmed by the volume of irrelevant promotional content. Inadequate understanding of patient and customer needs is one of the leading causes why drug launches underperform.
Sorcero unifies fragmented global data and real-world evidence into actionable, compliant intelligence. The platform integrates hundreds of sources to create a 360-degree view of over 40 million HCPs and 100 million published scientists worldwide. Medically-tuned AI agents ingest, analyze, and validate information to ensure 96.1% clinical inclusion accuracy, surpassing the 95% FDA regulatory threshold and PhD-level human performance.
Unlike traditional medical outreach informed primarily by U.S.-only claims data and prescription volumes, Sorcero reads more than 263 million publications and 1.3 billion citations globally, including every congress session, report, survey, CRM interaction, safety case, and medical inquiry. This identifies which KOLs and doctors are active in specific research areas or treating relevant patient populations. The platform continuously monitors product efficacy and safety, providing the precise, real-time insights precision medicine practitioners now expect, and allowing life sciences customers to engage HCPs with the right information at the right time.
Read More – Relixir Raises $2M in Seed Funding
